On September 23, 2026, Wedbush cut its Compass Therapeutics Inc. (CMPX) rating from Outperform to Neutral.
Among five firms active over the past 90 days, four hold a bullish rating. 13 analysts set consensus price targets as of October 30, 2026, with a mean of $6.03, a median of $6.12 and a range of $1.01 to $12.60.
Consensus Q4 FY2026 EPS is -$0.14, with revenue at $0. The next earnings report is on March 3, 2027.
